The expanding spectrum of neurological disorders of phosphoinositide metabolism
© 2019. Published by The Company of Biologists Ltd..
Phosphoinositides (PIPs) are a ubiquitous group of seven low-abundance phospholipids that play a crucial role in defining localized membrane properties and that regulate myriad cellular processes, including cytoskeletal remodeling, cell signaling cascades, ion channel activity and membrane traffic. PIP homeostasis is tightly regulated by numerous inositol kinases and phosphatases, which phosphorylate and dephosphorylate distinct PIP species. The importance of these phospholipids, and of the enzymes that regulate them, is increasingly being recognized, with the identification of human neurological disorders that are caused by mutations in PIP-modulating enzymes. Genetic disorders of PIP metabolism include forms of epilepsy, neurodegenerative disease, brain malformation syndromes, peripheral neuropathy and congenital myopathy. In this Review, we provide an overview of PIP function and regulation, delineate the disorders associated with mutations in genes that modulate or utilize PIPs, and discuss what is understood about gene function and disease pathogenesis as established through animal models of these diseases.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2019 |
|---|---|
| Erschienen: |
2019 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:12 |
|---|---|
| Enthalten in: |
Disease models & mechanisms - 12(2019), 8 vom: 13. Aug. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Volpatti, Jonathan R [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 06.04.2020 Date Revised 08.04.2020 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1242/dmm.038174 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM300234880 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM300234880 | ||
| 003 | DE-627 | ||
| 005 | 20231225102057.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2019 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1242/dmm.038174 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1000.xml |
| 035 | |a (DE-627)NLM300234880 | ||
| 035 | |a (NLM)31413155 | ||
| 035 | |a (PII)dmm038174 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Volpatti, Jonathan R |e verfasserin |4 aut | |
| 245 | 1 | 4 | |a The expanding spectrum of neurological disorders of phosphoinositide metabolism |
| 264 | 1 | |c 2019 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 06.04.2020 | ||
| 500 | |a Date Revised 08.04.2020 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a © 2019. Published by The Company of Biologists Ltd. | ||
| 520 | |a Phosphoinositides (PIPs) are a ubiquitous group of seven low-abundance phospholipids that play a crucial role in defining localized membrane properties and that regulate myriad cellular processes, including cytoskeletal remodeling, cell signaling cascades, ion channel activity and membrane traffic. PIP homeostasis is tightly regulated by numerous inositol kinases and phosphatases, which phosphorylate and dephosphorylate distinct PIP species. The importance of these phospholipids, and of the enzymes that regulate them, is increasingly being recognized, with the identification of human neurological disorders that are caused by mutations in PIP-modulating enzymes. Genetic disorders of PIP metabolism include forms of epilepsy, neurodegenerative disease, brain malformation syndromes, peripheral neuropathy and congenital myopathy. In this Review, we provide an overview of PIP function and regulation, delineate the disorders associated with mutations in genes that modulate or utilize PIPs, and discuss what is understood about gene function and disease pathogenesis as established through animal models of these diseases | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, N.I.H., Extramural | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a ALS | |
| 650 | 4 | |a Charcot Marie Tooth disease | |
| 650 | 4 | |a Congenital myopathy | |
| 650 | 4 | |a Neurogenetic | |
| 650 | 4 | |a Phosphoinositides | |
| 650 | 7 | |a Minor Histocompatibility Antigens |2 NLM | |
| 650 | 7 | |a Phosphatidylinositols |2 NLM | |
| 650 | 7 | |a Phosphotransferases (Alcohol Group Acceptor) |2 NLM | |
| 650 | 7 | |a EC 2.7.1.- |2 NLM | |
| 650 | 7 | |a phosphatidylinositol phosphate 4-kinase |2 NLM | |
| 650 | 7 | |a EC 2.7.1.67 |2 NLM | |
| 700 | 1 | |a Al-Maawali, Almundher |e verfasserin |4 aut | |
| 700 | 1 | |a Smith, Lindsay |e verfasserin |4 aut | |
| 700 | 1 | |a Al-Hashim, Aqeela |e verfasserin |4 aut | |
| 700 | 1 | |a Brill, Julie A |e verfasserin |4 aut | |
| 700 | 1 | |a Dowling, James J |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Disease models & mechanisms |d 2008 |g 12(2019), 8 vom: 13. Aug. |w (DE-627)NLM184855462 |x 1754-8411 |7 nnns |
| 773 | 1 | 8 | |g volume:12 |g year:2019 |g number:8 |g day:13 |g month:08 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1242/dmm.038174 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 12 |j 2019 |e 8 |b 13 |c 08 | ||